Amo Pharma (AgeTech UK) Biomed
Rare and orphan diseases, phase 3 clinical trials of GSK 3beta inhibitor, also glutamate modulator (Rett syndrome).
Technology:
AgeTech Companies
Industry:
UK AgeTech 2020
Headquarters:
United Kingdom
Founded Date:
N/A
Employees Number:
N/A
Funding Status:
N/A
Register and Claim Ownership